Navigation Links
Tocagen's First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma
Date:6/7/2011

SAN DIEGO, June 7, 2011 /PRNewswire/ -- Tocagen Inc. today announced the company is enrolling patients with recurrent high grade glioma, such as those with glioblastoma multiforme (GBM, Grade 4), in its first-in-human clinical trial of Toca 511.

The multicenter, open-label study is evaluating the safety and tolerability of single ascending doses of Toca 511 administered intratumorally followed by cycles of the prodrug 5-fluorocytosine (5-FC) in patients who have failed prior surgery and chemoradiation. Patients will receive a single dose of Toca 511, a gene transfer viral vector that delivers a cytosine deaminase (CD) gene to tumor cells. After the vector is allowed to spread through the tumor for approximately 4 weeks, patients receive a six-day course of oral 5-FC. In the tumor cells expressing the CD gene, 5-FC is converted by the CD enzyme into the anti-cancer drug 5-fluorouracil (5-FU). Subsequently, patients receive additional cycles of oral 5-FC monthly for up to six months.

"There are limited treatment options available for patients with glioblastoma. It is therefore a priority to explore potential new therapies to treat this form of cancer," said Timothy Cloughesy, M.D., Director of the Neuro-Oncology Program at the University California, Los Angeles Jonsson Cancer Center and a principal investigator for the Toca 511 study. "Toca 511 is a novel approach that offers new hope to combating this deadly disease."

In studies performed in animal models of GBM, nearly all animals treated with Toca 511 followed by 5-FC lived for the duration of the study (six months), compared to less than two months for control (untreated) animals. Toca 511 spread through the brain tumors and, following 5-FC treatment, marked tumor regression occurred while healthy brain tissue was unharmed.

"Unlike conventional cancer treatments in which toxic side effects limit how much drug can be given, Toca 511 has the potential to deliver cancer-killing drug to tumors without systemic side effects," said Harry E. Gruber, M.D., chief executive officer of Tocagen.  "We plan to present the clinical data from this study at a scientific conference focused on brain cancer."

About Tocagen

Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene transfer products for the treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511, the company's lead investigational product candidate, is being evaluated in a Phase I/II clinical trial in patients with recurrent high grade glioma (such as glioblastoma multiforme). Tocagen has received grant support from leading brain cancer foundations including, Accelerate Brain Cancer Cure (ABC2), the American Brain Tumor Association (ABTA), and the National Brain Tumor Society (NBTS). For more information about Tocagen or Toca 511 please visit www.tocagen.com.


'/>"/>
SOURCE Tocagen Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
2. Apollo Endosurgery Completes First-in-Human Cases With New OverStitch™ Endoscopic Suturing System
3. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
4. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
5. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
6. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
7. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
8. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
9. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
10. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
11. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... presentations and one poster presentation at PittCon ... Chicago IL.  Pittcon is the world,s largest ... science and serves a wide array of ... sciences, pharmaceutical discovery and QA, food safety, ...
(Date:2/23/2017)... This report analyzes analyzes the worldwide markets for Wound Debridement Products ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 Mixed ... The mixed tocopherols market is projected to reach ... from 2016. The market is driven by factors such as ... & beverages and in feed, and regulations for sourcing, processing, ... for mixed tocopherols from emerging markets such as the ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... medicine in recent years. The technology is so cutting edge, in fact, the ... protocol for stem cell procedures. However, successful patient outcomes in certain clinical stem ...
(Date:2/22/2017)... ... 22, 2017 , ... The National Academy of Certified Care ... April 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification ... is periodically re-calibrated to ensure that newly certified professionals are prepared to work ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leverages advanced data analytics to accurately understand each Medicare Advantage member’s risk, ... a given population. This new solution helps transform the HCC Risk Adjustment ...
(Date:2/22/2017)... ... ... Doctors on Liens is continuing its steady expansion of medical specialties throughout ... North Valley Eye Medical Group in Mission Hills . Eye injuries and vision ... cases. These injuries have a major impact on the quality of life of ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Using the power ... utilizing a simple online checklist. Over a period of just 24 months, thousands of ... of an online checklist called T.A.D. , “The internet is not getting quieter. In ...
Breaking Medicine News(10 mins):